A study of Cordyceps Capsules as an Add-On Therapy in patients with moderate COVID 19 Infectio

Not Applicable

Completed

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J00-J99- Diseases of the respiratory system

• Registration Number: CTRI/2020/09/028131
• Lead Sponsor: Ambrosia Food Farm Co

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-03-21
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Patients with mild to Moderate Category COVID-19 patients

2.Male or female patients �18 years of age.

3.Patients with or without co-morbidities (stable diabetes or/and hypertension with medications).

4.Voluntary willingness to give written informed consent prior to participation in trial.

5.Male patients who is willing to follow contraceptive measures .

6.Female should be of non-childbearing potential, either surgically sterile or postmenopausal.

7.Female of childbearing potential should agree to use effective contraceptive measures

8.Willingness and ability to comply with trial and follow-up procedures.

Exclusion Criteria

1.Patients who refuse to give consent for participation.

2.Patients with severe COVID-19 infection

3.Patient with asymptomatic infection.

4.Patients who are allergic to Cordyceps Capsules.

5.Patients already enrolled in another intervention trial.

6.Patients who receive immunomodulant therapy like Tocilizumab or convalescent plasma or high-dose pulse steroid therapy.

7.Autoimmune diseases such as multiple sclerosis (MS), systemic lupus erythematosus (SLE) rheumatoid arthritis (RA) other conditions.

8.Patients with any bleeding disorder e.g. hemophilia and von Willebrand disease.

9.Patients in whom the surgeries are planned during the study.

10.Pregnant or breastfeeding.

11.Concurrent condition that in the investigatorââ?¬•s opinion would jeopardize compliance with the protocol.

12.Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.

Study & Design

• Study Type: Interventional
• Study Design: Not specified